Lenalidomid Teva B.V. (Lenalidomide)

Lenalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase complex, leading to selective degradation of transcription factors Ikaros and Aiolos. This results in enhanced immune cell activity, inhibition of angiogenesis, and induction of apoptosis in malignant plasma and lymphoid cells.

The specific dose and schedule of Lenalidomid Teva B.V. are determined by the prescribing physician based on the patient’s diagnosis, disease stage, renal function, and other clinical factors. No fixed dosing information is provided here.

Lenalidomid Teva B.V. is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because of a high risk of fetal harm. Breastfeeding is not recommended, as the drug may be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lenalidomide is a second‑generation IMiD, offering greater potency and a more favorable safety profile than thalidomide, while generally being better tolerated than the newer agent pomalidomide. Choice among these agents depends on disease‑specific factors, prior therapy, and individual patient tolerance.

Store Lenalidomid Teva B.V. at ambient temperature, preferably below 25 °C, in the original packaging. Protect the product from moisture and direct light to maintain stability throughout its shelf life.

The medication is administered orally, usually as a tablet taken with or without food, according to the prescriber’s instructions. Patients should swallow the tablet whole and follow any specific guidance regarding timing relative to meals.

Key serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe cutaneous reactions like Stevens‑Johnson syndrome, and the possible development of secondary malignancies such as acute myeloid leukemia. Prompt medical attention is required if any of these occur.

Lenalidomid Teva B.V. should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with severe renal impairment unless dose adjustments and close monitoring are implemented by a qualified clinician.